Squaryl TLR7/8 Ligands for Reduced Systemic Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing Toll-like receptor (TLR) ligands, particularly TLR7/8 ligands, face challenges such as systemic toxicity, leading to limited use and instability in acidic conditions, which hampers their effectiveness as vaccine adjuvants in cancer immunotherapy.
Innovation Solution
Development of novel compounds containing a squaryl group, specifically designed to enhance immune response and stability, reducing systemic toxicity and improving yields, with specific structural modifications to enhance their use as vaccine adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If early versions of TLR7/8 ligands are used, then immune response is activated, but systemic toxicity increases and limits use to topical administration
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of TLR7/8 ligands through squaryl group incorporation and lipidation. These structural parameter changes reduce systemic toxicity while preserving immune response activation, enabling transition from topical to systemic administration routes.
Solution Approach 2:
The patent employs composite materials by creating lipidated TLR7/8 ligand structures that combine the active ligand moiety with lipid components. This composite approach reduces systemic toxicity and enables both topical and systemic administration while maintaining immunostimulatory activity.
2Adaptability or versatility
If TLR ligands are administered systemically, then broader therapeutic application is possible, but instability in acidic conditions increases
Solution Approach 1:
The patent uses parameter changes by introducing squaryl groups and lipid modifications to the TLR ligand structure. These chemical parameter changes enhance stability in acidic conditions while maintaining the ability to function across different administration routes including systemic and topical routes.
3Ease of manufacture
If conventional TLR ligands are synthesized, then production is achievable, but yields are low and by-products are generated
Solution Approach 1:
The patent applies segmentation by dividing the synthesis into modular steps with the squaryl group serving as a central building block. This segmented approach to constructing the TLR ligand structure improves synthesis efficiency, increases yields, and reduces unwanted by-products through more controlled reaction pathways.
Data Source
AI summary
The present disclosure provides compounds of formula (I), (Ia), and (Ib), squaryl group- containing toll-like receptor ligands Also provided are pharmaceutical compositions and vaccine composition thereof and methods of treating a disease of disorder with the compounds and composition described herein.